{"classes":[{"categories":[{"measurements":[{"comment":"Single value, not amenable to calculation of standard deviation","groupId":"OG000","spread":"NA","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"IMWG: Progressive"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.42","value":"0.90"},{"groupId":"OG001","spread":"0.59","value":"0.99"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"IMWG: Partial Response"},{"categories":[{"measurements":[{"comment":"Single value, not amenable to calculation of standard deviation","groupId":"OG000","spread":"NA","value":"1.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"title":"IMWG: Very Good Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"description":"Secondary Objective 1: To assess whether the novel Magnetic Resonance (MR) protocol can improve detection of longitudinal changes in tumour burden in patients with new or relapsed myeloma during therapy, compared to the International Myeloma Working Group (IMWG) Response Group classification alone.\n\nThis section compared two indicators of therapy response:\n\n1. IMWG Response Group classification \\[1\\], based on % change in serum paraprotein\n2. % change in Apparent Diffusion Coefficient (ADC) measurements in participants where there was a lytic bone lesion identified on both baseline and follow-up novel MR scan amenable to ADC measurement \\[2\\].\n\nRef:\n\n1. https://www.myeloma.org/resource-library/international-myeloma-working-group-imwg-uniform-response-criteria-multiple\n2. Messiou, Christina, et al. \"Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS).\" Radiology 291.1 (2019): 5-13","dispersionType":"Standard Deviation","groups":[{"description":"Patients with new myeloma who had a lytic bone lesion amenable to longitudinal ADC measurement, and IMWG response classification.","id":"OG000","title":"Group 1a: New Myeloma"},{"description":"Patients with relapsed myeloma who had a lytic bone lesion amenable to longitudinal ADC measurement, and IMWG response classification.","id":"OG001","title":"Group 1b: Relapsed Myeloma"}],"paramType":"MEAN","populationDescription":"Participants who had successfully measured paired serum paraprotein (amenable to IMWG Response Group classification) and novel MR scans (with a lytic bone lesion amenable to ADC measurement, with a successfully calculated % change in ADC) at baseline and 6-month follow-up.","reportingStatus":"POSTED","timeFrame":"Comparison between baseline and follow-up at 6month","title":"Secondary Outcome 1: Detect Longitudinal Changes in Tumour Load With Therapy [% Change in ADC (Apparent Diffusion Coefficient) vs IMWG (International Myeloma Working Group) Response Group Classification]","type":"SECONDARY","unitOfMeasure":"ADC Ratio (follow-up / baseline)"}